Fareston(toremifene)
Fareston, Toremifene (toremifene) is a small molecule pharmaceutical. Toremifene was first approved as Fareston on 1996-02-14. It is used to treat breast neoplasms and hormone-dependent neoplasms in the USA. It has been approved in Europe to treat breast neoplasms.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Toremifene (discontinued: Fareston)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Toremifene citrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FARESTON | Kyowa Kirin | N-020497 DISCN | 1997-05-29 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fareston | New Drug Application | 2023-09-15 |
| toremifene citrate | ANDA | 2020-08-20 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| breast neoplasms | EFO_0003869 | D001943 | C50 |
| hormone-dependent neoplasms | — | D009376 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
38 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 8 | 11 | 4 | 3 | 25 |
| Male breast neoplasms | D018567 | — | — | — | — | 1 | 1 | — | 2 |
| Breast carcinoma in situ | D000071960 | — | D05 | — | — | — | 1 | — | 1 |
| Invasive hydatidiform mole | D002820 | — | D39.2 | — | — | — | 1 | — | 1 |
| Postmenopause | D017698 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | 2 | 4 | — | — | 6 |
| Hormone-dependent neoplasms | D009376 | — | — | — | — | 3 | — | — | 3 |
| Prostatic neoplasms | D011471 | — | C61 | — | 1 | 2 | — | — | 3 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | 2 | — | — | 2 |
| Prostatic intraepithelial neoplasia | D019048 | — | N42.31 | — | 1 | 1 | — | — | 2 |
| Carcinoma in situ | D002278 | — | D09.9 | — | 1 | 1 | — | — | 2 |
| Amenorrhea | D000568 | — | N91.2 | — | — | 1 | — | — | 1 |
| Mastodynia | D059373 | EFO_1001366 | N64.4 | — | — | 1 | — | — | 1 |
| Osteoporosis | D010024 | HP_0000939 | M81.0 | — | — | 1 | — | — | 1 |
| Precancerous conditions | D011230 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aggressive fibromatosis | D018222 | — | D48.11 | — | 2 | — | — | — | 2 |
| Urologic neoplasms | D014571 | — | C64-C68 | — | 1 | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | — | — | — | 1 |
| Transitional cell carcinoma | D002295 | — | — | — | 1 | — | — | — | 1 |
| Covid-19 | D000086382 | — | — | — | 1 | — | — | — | 1 |
| Fibroma | D005350 | — | M72.9 | — | 1 | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
| Ovarian epithelial carcinoma | D000077216 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intraductal carcinoma noninfiltrating | D002285 | — | D05.1 | — | — | — | — | 1 | 1 |
| Vision disorders | D014786 | HP_0000505 | H53.11 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Toremifene |
| INN | toremifene |
| Description | Toremifene is a tertiary amine, an organochlorine compound and an aromatic ether. It has a role as an antineoplastic agent, an estrogen antagonist, an estrogen receptor modulator and a bone density conservation agent. It derives from a hydride of a stilbene. |
| Classification | Small molecule |
| Drug class | antiestrogens of the clomifene and tamoxifen groups |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 89778-26-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1655 |
| ChEBI ID | 9635 |
| PubChem CID | 3005573 |
| DrugBank | DB00539 |
| UNII ID | 7NFE54O27T (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Toremifene
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,402 documents
View more details
Safety
Black-box Warning
Black-box warning for: Fareston, Toremifene citrate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
435 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use